[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAPMXaodj3W6VV8v8CWh9uGKSLPRbjHg-ZPJ4lTIsJJxk",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RAPMXaodj3W6VV8v8CWh9uGKSLPRbjHg-ZPJ4lTIsJJxk#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RAPMXaodj3W6VV8v8CWh9uGKSLPRbjHg-ZPJ4lTIsJJxk#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RAPMXaodj3W6VV8v8CWh9uGKSLPRbjHg-ZPJ4lTIsJJxk#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAPMXaodj3W6VV8v8CWh9uGKSLPRbjHg-ZPJ4lTIsJJxk#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/DOID_5419",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAPMXaodj3W6VV8v8CWh9uGKSLPRbjHg-ZPJ4lTIsJJxk#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/DOID_5419"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/drugbank:DB00408"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "adasuve psychomotor agitation is defined in dsm iv as excessive motor activity associated with a feeling of inner tension patients experiencing agitation often manifest behaviors that interfere with their care e g threatening behaviors escalating or urgently distressing behavior self exhausting behavior leading clinicians to the use of rapidly absorbed antipsychotic medications to achieve immediate control of the agitation see clinical studies 14 the efficacy of adasuve was established in one study of acute agitation in patients with schizophrenia and one study of acute agitation in patients with bipolar i disorder see clinical studies 14 limitations of use as part of the adasuve rems program to mitigate the risk of bronchospasm adasuve must be administered only in an enrolled healthcare facility see warnings and precautions 5 2 adasuve is a typical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar i disorder in adults efficacy was demonstrated in 2 trials in acute agitation one in schizophrenia and one in bipolar i disorder 1 14 limitations of use adasuve must be administered only in an enrolled healthcare facility 1"
    } ],
    "https://w3id.org/biolink/vocab/association_type" : [ {
      "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation"
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://w3id.org/um/neurodkg/SymptomaticReliefIndication"
    } ]
  }, {
    "@id" : "https://identifiers.org/drugbank:DB00408",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAPMXaodj3W6VV8v8CWh9uGKSLPRbjHg-ZPJ4lTIsJJxk#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAPMXaodj3W6VV8v8CWh9uGKSLPRbjHg-ZPJ4lTIsJJxk#assertion",
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAPMXaodj3W6VV8v8CWh9uGKSLPRbjHg-ZPJ4lTIsJJxk#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAPMXaodj3W6VV8v8CWh9uGKSLPRbjHg-ZPJ4lTIsJJxk",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-07-03T12:43:32.281+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAPMXaodj3W6VV8v8CWh9uGKSLPRbjHg-ZPJ4lTIsJJxk#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "RjMP0wQPbbBdkRJ8WKc1HR4ARuOOwCjWFF81fKf8j71nSRkfDB8OVTCA7FadYWovAwy8KpWXbaHfqH8rCJpFzjCb0a1x9XhKLAfRUVee9wCpggbxAVDhggi7UgyBk0Az8uXvs6NkF78kgv6HBHDTT5b/kntFJJmgeEpTS4nsbng="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RAPMXaodj3W6VV8v8CWh9uGKSLPRbjHg-ZPJ4lTIsJJxk"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAPMXaodj3W6VV8v8CWh9uGKSLPRbjHg-ZPJ4lTIsJJxk#pubinfo"
} ]